Pricing Log in Create free account

Galecto, Inc. (DMRA) vs Taysha Gene Therapies, Inc. (TSHA)

Galecto, Inc. and Taysha Gene Therapies, Inc. are both Biotechnology companies. Galecto, Inc. and Taysha Gene Therapies, Inc. are of similar size ($1.2B and $1.2B). Across the 10 metrics below, Galecto, Inc. leads on 7 and Taysha Gene Therapies, Inc. on 3.

Valuation

Metric DMRA TSHA Biotechnology median
P/E n/m n/m 8.50
P/S n/m 113.26 9.71
P/B 2.92 3.45 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 78.83 9.21
Earnings yield (816.76%) (11.60%) (33.15%)
Free cash flow yield (3.96%) (10.41%) (25.50%)

Profitability

Metric DMRA TSHA Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (26.26%) (47.05%) (56.36%)
Return on assets (18.64%) (37.23%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DMRA TSHA Biotechnology median
Revenue growth (TTM) — 18.96% 6.02%
EPS growth (last fiscal year) (730.84%) 5.56% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMRA TSHA Biotechnology median
Debt to equity 0.00 0.13 0.00
Current ratio 19.73 17.76 4.72
Net debt to EBITDA 1.22 2.47 0.96

Dividend

Metric DMRA TSHA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DMRA TSHA Biotechnology median
Market cap 1.16b 1.22b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack